Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

類似資料

• Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
  著者:: Dumas, Pierre-Yves, 等
  出版事項: (2020)
• Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
  著者:: Sarah Bertoli, 等
  出版事項: (2020-03-01)
• Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
  著者:: Pierre-Yves Dumas, 等
  出版事項: (2020-07-01)
• Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
  著者:: Dumas, Pierre-Yves, 等
  出版事項: (2020)
• CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
  著者:: Vergez, François, 等
  出版事項: (2020)